Navigation Links
Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
Date:12/1/2011

atients with rare hereditary problems of galactose intolerance, severe lactase deficiency with a severe degree of intolerance to lactose-containing products, or of glucose-galactose malabsorption.
  • Women of childbearing potential should avoid becoming pregnant while taking TASIGNA and should be advised of the potential hazard to the fetus if they do. The safety and effectiveness of TASIGNA in pediatric patients have not been established.
  • In newly diagnosed Ph+ CML-chronic phase, the most commonly reported nonhematologic adverse drug reactions (>10%) were rash, pruritus, headache, nausea, fatigue, and myalgia.
  • In resistant or intolerant Ph+ CML-chronic phase, the most commonly reported nonhematologic adverse drug reactions (greater than or equal to 10%) were rash, pruritus, nausea, fatigue, headache, constipation, diarrhea, vomiting, and myalgia.
  • In resistant or intolerant Ph+ CML-accelerated phase, the most commonly reported nonhematologic adverse drug reactions (greater than or equal to 10%) were rash, pruritus, and fatigue.
  • TASIGNA may need to be temporarily withheld and/or dose reduced for QT prolongation, hematologic toxicities that are not related to underlying leukemia, clinically significant moderate or severe nonhematologic toxicities, laboratory abnormalities, or concomitant use of strong CYP3A4 inhibitors.
  • Please see full Prescribing Information including Boxed Warning.

    About Gleevec
    Gleevec® (imatinib mesylate) tablets are indicated for newly diagnosed adult patients with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in the chronic phase (CP). Gleevec is also indicated for the treatment of patients with Ph+ CML in blast crisis (BC), accelerated phase (AP), or in CP after failure of interferon-alpha therapy.

    GLEEVEC Important Safety Information
    GLEEVEC is often associated wit
    '/>"/>

    SOURCE Novartis Pharmaceuticals Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

    Related biology technology :

    1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
    2. Genentech and Novartis Remain Image Leaders in Oncology and Hematology
    3. FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD
    4. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
    5. With the Recent Launch of Novartiss Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch
    6. VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
    7. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
    8. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
    9. Novartis Class Awarded $250 Million in Punitive Damages
    10. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
    11. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/23/2014)... LOS ANGELES , July 23, 2014 /PRNewswire-iReach/ -- ... enhance cognitive performance for the long term. They are ... competitive edge of sustained energy as an alternative to ... launch Think Drinks on Indiegogo on July 29, 2014, ... the 30-day campaign. Photo - http://photos.prnewswire.com/prnh/20140723/129697 ...
    (Date:7/23/2014)... Last year, Formedix celebrated its ... provider of data management solutions for clinical trials. The ... for electronic data capture (EDC) and clinical data management. ... execution tools added TrialMaster to its Transform for EDC ... Transform for TrialMaster, is being released this week, in ...
    (Date:7/23/2014)... July 23, 2014 StemGenex® , ... in the US aimed at improving the lives of ... clinical study for Parkinson’s disease. StemGenex believes that ... cell therapy are paramount when providing care to patients ... makes stem cell therapy accessible to the millions of ...
    (Date:7/23/2014)... - BioAmber Inc. (NYSE: BIOA ), ... that the underwriters of its common stock offering ... additional 420,000 shares of common stock at the ... underwriting discounts and commissions, in connection with its ... of common stock, bringing the expected net proceeds ...
    Breaking Biology Technology:truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3
    ... of Wisconsin-Madison researchers about their work in games and education, ... used in academics. The first interview is with Dr. James ... of Curriculum and Instruction in the School of Education at ... to Teach Us About Learning and Literacy. Dr. Gee received ...
    ... Byrnes Lets Get Serious Column that first appeared on ... deal of mail with healthy debate and discussion among many members ... that should help to clarify Mr. Byrnes position. John Byrnes ... am not an enemy of manufacturing ,Contrary to impressions gleaned ...
    ... Key to Reviving the Economy , ,* * * * ... ,We're back from last week's DEMOmobile 2003, and the experience has ... to reviving the overall economy. The energy from the 400-plus attendees ... thing became crystal clear: True connectivity -- both in our homes ...
    Cached Biology Technology:The Learning Game - Researchers Study Video Gaming Principles that Apply to Education 2The Learning Game - Researchers Study Video Gaming Principles that Apply to Education 3The Learning Game - Researchers Study Video Gaming Principles that Apply to Education 4The Learning Game - Researchers Study Video Gaming Principles that Apply to Education 5The Learning Game - Researchers Study Video Gaming Principles that Apply to Education 6Lets Get Serious: Another Look 2Lets Get Serious: Another Look 3The News From DEMOmobile 2003 2The News From DEMOmobile 2003 3
    (Date:7/23/2014)... that has the entire country in its grip is affecting ... be responsible for the proliferation of a heat-loving amoeba commonly ... hot springs, which the drought has made warmer than usual ... an infection caused by this parasite after swimming in several ... of an individual and travels to the brain. Nose plugs ...
    (Date:7/23/2014)... blow fly Chrysomya megacephala is commonly found ... to determine the time of death, referred to as ... form of C. megacephala from Tamil Nadu ... features and molecular characterization through generation of DNA barcoding. ... the open access Biodiversity Data Journal . , ...
    (Date:7/23/2014)... around the world by 2050, according to one of ... Change (IPCC), may be advantageous to the physiology and ... of forage plants such as Stylosanthes capitata Vogel ... countries such as Brazil., The conclusion is from a ... Biology at the Ribeiro Preto Faculty of Philosophy, Sciences ...
    Breaking Biology News(10 mins):Diseases of another kind 2Dead body feeding larvae useful in forensic investigations 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 4
    ... warming most global climate models predict will do more harm ... It will make drastic changes in fragile ecosystems throughout the ... during the last few decades in the Antarctic Peninsula has ... the abundance of krill that are at the base of ...
    ... ratio of white blood cell types may help ... mononucleosis and bacterial tonsillitis, potentially guiding treatment decisions, ... of Archives of Otolaryngology–Head & Neck Surgery, one ... of the tonsils) and infectious mononucleosis (caused by ...
    ... malfunction that causes a form of mental retardation called ... of two types of cells in the developing embryonic ... genetic abnormality gives rise to the neural pathology of ... into the mechanism underlying NS could apply to other ...
    Cached Biology News:Antarctic warming to reduce animals at base of ecosystem, shift some penguin populations southward 2Common blood test can help distinguish between mononucleosis and tonsillitis 2How genetic malfunction causes a form of retardation 2